6-Methyl-MDA

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar laws in other countries)
Identifiers
IUPAC name 1-(6-Methyl-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number	246861-21-2
PubChem CID	10511982
ChemSpider	8687383 Y
ChEMBL	ChEMBL6376 Y
Chemical and physical data
Formula	C11H15NO2
Molar mass	193.246 g·mol−1
3D model (JSmol)	Interactive image
SMILES O1c2cc(c(cc2OC1)CC(N)C)C
InChI InChI=1S/C11H15NO2/c1-7-3-10-11(14-6-13-10)5-9(7)4-8(2)12/h3,5,8H,4,6,12H2,1-2H3 Y Key:HCFHWXDIZOAUTQ-UHFFFAOYSA-N Y
(verify)

6-Methyl-3,4-methylenedioxyamphetamine (6-Methyl-MDA) is an entactogen and psychedelic drug of the amphetamine class.^[1] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-methylamphetamine (MDMA).^[1]

6-Methyl-MDA has IC₅₀ values of 783 nM, 28,300 nM, and 4,602 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.^[1] In animal studies it substitutes for MBDB, MMAI, LSD, and 2,5-dimethoxy-4-iodoamphetamine (DOI), though not amphetamine, but only partially and at high doses.^[1] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active,^[1] and appropriate doses may be similar to or somewhat higher than those of MDMA.^{[citation needed]}